Education background :
- Ph.D in biochemistry, University Paris 6 1982.
- Doctorat es Sciences, University Paris 6, 1985
2- Professional Experience :
1983-1992 INSERM Research scientist (INSERM U99).
1984 Visiting scientist, Mc Master University, Hamilton, Canada
1990 and 1991Visiting scientist, University of Liverpool, Liverpool, England
1992- 2002: Director of research (INSERM U99).
2003-2006 Director of research (INSERM U581)
2007- Director of research (Institut Mondor de Recherche Biomédicale)
2004- Interface grant with AP-HP
3- Membership of professional organizations and scientific expertise
-Member of several french scientific committes (INSERM, AERES, ANR for recruitment, grants and scientific evaluation)
-Member of the PhD program committee University Paris Est
-International scientific expertise (European Community, Israelian scientific Foundation, Swiss National Foundation, American University of Beyrouth, Spanish minister of health, german Volswagen Foundation etc..)
-Member of the governing board of the French Association for the Study of the Liver (since 2008)
-Chairman of the Scientific Council of the National Research Program in Hepatology and Gastroenterology (2006-2008)
-Member of the scientific council of Ciberehd, Spain (centro de investigacion biomedica en red enfermaded hepaticas y digestivas)
-Member of the scientific council of the International Society of Hepatic Sinusoidal Research
4- Editorial Activity
-Associate Editor of American Journal of Physiology-Cell Physiology (since 2008)
-Member of the Editorial Board of American Journal of Physiology –Cell Physiology (1999-2008) and Gastrointestinal –Liver (since 2009)
-Member of the Editorial Board of Molecular Pharmacology (2003-present)
My research laboratory carries out research ion liver pathophysiology, focussing on the regulation of inflammation, regeneration and fibrogenesis, and the identification of novel therapeutic targets.
Over the last years, we have demonstrated that the endocannabinoid system represents a particularly interesting antifibrogenic therapeutic target, because of the antifibrogenic properties of the CB2 receptor and the profibrogenic properties of the CB1 receptor. Moreover, we have established that the CB2 receptor is an overall protective pathway with antiinflammatory effects and beneficial impact on alcoholic fatty liver, hepatocyte survival and regeneration. We are further studying the therapeutic potential of novel molecules targeting cannabinoid receptors. More generally, we are currently investigating the impact of inflammation on the development chronic liver diseases, and study the interplay of inflammatory cells with fibrogenic and parenchymal cells, with the aim to identify novel antiinflammatory targets with potential antifibrogenic effects. Our projects combine clinical studies and experimental approaches in murine and cellular models, within the framework of a close local collaboration between our group and the Hepatology-Gastroenterology, Medical imaging, Pathology departments of CHU Mondor, as well as of numerous national and international collaborations. Our research is financed by public contracts, foundations and industrial partners.